免疫複合体膜性増殖性糸球体腎炎（IC-MPGN） - 市場考察、疫学、市場予測（2034年）

主なハイライト

• 主要7市場の2023年のIC-MPGNの市場規模は1,700万米ドルで、IC-MPGNの診断有病率の増加と価格の高い新治療法の参入により、2034年までに拡大すると予測されます。
• 英国の成人は小児に比べIC-MPGNの有病率が高いです。IC-MPGN患者の約7％が小児で、約93％が成人です。

免疫複合体膜性増殖性糸球体腎炎（IC-MPGN）市場の見通し

• 米国における2023年のIC-MPGNの市場規模は約1,200万米ドルで、新治療法の上市により拡大が見込まれます。
• 欧州4ヶ国・英国の中では、2023年にドイツが最大の収益シェアを獲得し、スペインとフランスがこれに続きました。
• Apellis Pharmaceuticalsのpegcetacoplanは、IC-MPGNにおいてNovartisのiptacopanよりも先行者利益を得ると予測されます。

当レポートでは、免疫複合体膜性増殖性糸球体腎炎（IC-MPGN）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 IC-MPGNのエグゼクティブサマリー

第4章 IC-MPGN市場の概要

• 主要7市場のIC-MPGNの市場シェア分布：治療法別（2023年）
• 主要7市場のIC-MPGNの市場シェア分布：治療法別（2034年）

第5章 主な出来事

第6章 疫学と市場予測手法

第7章 疾患の背景と概要

• イントロダクション
• 種類
• 病因
• 臨床所見
• 組織学的パターン
• 診断

第8章 治療

• 特発性IC-MPGN

第9章 Clinical Practice Guideline for the Management of Glomerular Diseases、KDIGO 2021

• ICGN
• C3GまたはIC-MPGNの管理アルゴリズム

第10章 疫学と患者人口

• 主な調査結果
• IC-MPGNの前提条件と理論的根拠
• 主要7市場のIC-MPGNと診断された総患者数
• 米国
• 欧州4ヶ国・英国
• 日本

第11章 ペイシェントジャーニー

第12章 新治療法

• 主な競合
• Iptacopan (LNP023): Novartis Pharmaceuticals
• Pegcetacoplan (APL-2): Apellis Pharmaceuticals

第13章 IC-MPGN：主要7市場の分析

• 主な調査結果
• 主要7市場のIC-MPGNの総市場規模
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
• 米国の市場規模
  • 米国のIC-MPGNの総市場規模
  • 米国のIC-MPGNの市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のIC-MPGNの総市場規模
  • 欧州4ヶ国・英国のIC-MPGNの市場規模：治療法別
• 日本の市場規模
  • 日本のIC-MPGNの総市場規模
  • 日本のIC-MPGNの市場規模：治療法別

第14章 アンメットニーズ

第15章 SWOT分析

第16章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本
• IC-MPGN：市場参入と償還

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

List of Tables

• Table 1: Summary of IC-MPGN Market, and Epidemiology (2020-2034)
• Table 2: Total Diagnosed Prevalent Population of IC-MPGN in the 7MM (2020-2034)
• Table 3: Total Diagnosed Prevalent Population of IC-MPGN in the United States (2020-2034)
• Table 4: Gender-specific Diagnosed Prevalent Population of IC-MPGN in the United States (2020-2034)
• Table 5: Age-specific Diagnosed Prevalent Population of IC-MPGN in the United States (2020-2034)
• Table 6: Total Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK (2020-2034)
• Table 7: Gender-specific Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK (2020-2034)
• Table 8: Age-specific Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK (2020-2034)
• Table 9: Total Diagnosed Prevalent Population of IC-MPGN in Japan (2020-2034)
• Table 10: Gender-specific Diagnosed Prevalent Population of IC-MPGN in Japan (2020-2034)
• Table 11: Age-specific Diagnosed Prevalent Population of IC-MPGN in Japan (2020-2034)
• Table 12: Comparison of Emerging Drugs Under Development
• Table 13: Iptacopan, Clinical Trial Description, 2024
• Table 14: Pegcetacoplan (APL-2), Clinical Trial Description, 2024
• Table 15: Market Size of IC-MPGN in the 7MM, USD million (2020-2034)
• Table 16: Key Market Forecast Assumption of IC-MPGN in the United States
• Table 17: Key Market Forecast Assumption of IC-MPGN in EU4 and the UK
• Table 18: Key Market Forecast Assumption of IC-MPGN in Japan
• Table 19: Market Size of IC-MPGN in the US, USD million (2020-2034)
• Table 20: Market Size of IC-MPGN by Therapies in the US, USD million (2020-2034)
• Table 21: Market Size of IC-MPGN in EU4 and the UK, USD million (2020-2034)
• Table 22: Market Size of IC-MPGN by therapies in EU4 and the UK, USD million (2020-2034)
• Table 23: Market Size of IC-MPGN in Japan, USD million (2020-2034)
• Table 24: Market Size of IC-MPGN by Therapies in Japan, USD million (2020-2034)

List of Figures

• Figure 1: Classification of MPGN Based on Immunofluorescence Findings
• Figure 2: Histological Patterns
• Figure 3: Algorithm for Management of C3G or IC-MPGN
• Figure 4: Total Diagnosed Prevalent Population of IC-MPGN in the 7MM (2020-2034)
• Figure 5: Total Diagnosed Prevalent Population of IC-MPGN in the United States (2020-2034)
• Figure 6: Gender-specific Diagnosed Prevalent Population of IC-MPGN in the United States (2020-2034)
• Figure 7: Age-specific Diagnosed Prevalent Population of IC-MPGN in the United States (2020-2034)
• Figure 8: Total Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK (2020-2034)
• Figure 9: Gender-specific Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK (2020-2034)
• Figure 10: Age-specific Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK (2020-2034)
• Figure 11: Total Diagnosed Prevalent Population of IC-MPGN in Japan (2020-2034)
• Figure 12: Gender-specific Diagnosed Prevalent Population of IC-MPGN in Japan (2020-2034)
• Figure 13: Age-specific Diagnosed Prevalent Population of IC-MPGN in Japan (2020-2034)
• Figure 14: Market Size of IC-MPGN in the 7MM, USD million (2020-2034)
• Figure 15: Market Size of IC-MPGN in the US, USD million (2020-2034)
• Figure 16: Market Size of IC-MPGN by Therapies in the US, USD million (2020-2034)
• Figure 17: Market Size of IC-MPGN in EU4 and the UK, USD million (2020-2034)
• Figure 18: Market Size of IC-MPGN by Therapies in EU4 and the UK, USD million (2020-2034)
• Figure 19: Market Size of IC-MPGN in Japan, USD million (2020-2034)
• Figure 20: Market Size of IC-MPGN by Therapies in Japan, USD million (2020-2034)
• Figure 21: Health Technology Assessment
• Figure 22: Reimbursement Process in Germany
• Figure 23: Reimbursement Process in France
• Figure 24: Reimbursement Process in Italy
• Figure 25: Reimbursement Process in Spain
• Figure 26: Reimbursement Process in the United Kingdom
• Figure 27: Reimbursement Process in Japan
• Figure 28: Complement Activation is Implicated in Numerous Diseases

Key Highlights:

• The market size of IC-MPGN in the 7MM was ~USD 17 million in 2023 and is expected to increase by 2034 due to an increase in the diagnosed prevalence of IC-MPGN and the entry of emerging therapies with a premium price tag.
• Since there are no approved therapies for IC-MPGN, the market is mainly dominated by the use of off-label prescription drugs. Treatments for IC-MPGN include immunosuppressants, steroids, renin-angiotensin-aldosterone system Inhibitors (RAAS), and other supportive therapies (calcineurin inhibitors, other immunosuppressive agents, and antibodies).
• Upcoming anti-complements such as iptacopan and pegcetacoplan present a realistic therapeutic option for complement-related diseases.
• Adults population is more prevalent towards IC-MPGN compared to the pediatric population. Approximately ~7% of the population of IC-MPGN in the UK are pediatric and ~93% are adults.

DelveInsight's "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), historical and forecasted epidemiology as well as Immune Complex Membranoproliferative Glomerulonephritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Immune Complex Membranoproliferative Glomerulonephritis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Immune Complex Membranoproliferative Glomerulonephritis market size from 2020 to 2034. The report also covers current Immune Complex Membranoproliferative Glomerulonephritis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034.

Immune Complex Membranoproliferative Glomerulonephritis Disease Understanding and Treatment Algorithm

Immune Complex Membranoproliferative Glomerulonephritis Overview

Membranoproliferative glomerulonephritis (MPGN) is a kidney disorder involving inflammation and kidney cell changes. It is a form of glomerulonephritis caused by an abnormal immune response.

MPGN has previously been used as an umbrella term to describe a spectrum of hypocomplementemic glomerular diseases, which are a rare cause of end-stage kidney disease (ESKD). More recently, MPGN has been reclassified into two diseases: immune-complex MPGN (IC-MPGN) and C3 glomerulopathy (C3G) based on immunofluorescence findings in kidney biopsies: predominant or exclusive C3 deposits in C3G and combined immunoglobulins and complement deposits in IC-MPGN.

Immune Complex Membranoproliferative Glomerulonephritis Diagnosis

To diagnose MPGN, several tests are typically conducted including a Urine test, Blood test, Glomerular Filtration Rate (GFR) test, Kidney biopsy, and Genetic testing. These tests collectively aid in confirming the diagnosis of MPGN, determining its specific class, understanding the extent of kidney involvement, and guiding healthcare providers in formulating the most effective treatment plan based on the underlying causes and characteristics of the disease

Immune Complex Membranoproliferative Glomerulonephritis Treatment

To date, there has not been a specific treatment devised to cure the indication completely. Besides, the market for IC-MPGN lacks approved drugs and is dominated by the use of off-label prescription medications. These include immunosuppressants, corticosteroids, renin-angiotensin-aldosterone system Inhibitors (RAAS), and other supportive therapies.

Further details related to treatment are provided in the report…

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by a total diagnosed prevalent population of Immune Complex Membranoproliferative Glomerulonephritis, gender-specific diagnosed prevalent population of Immune Complex Membranoproliferative Glomerulonephritis, and age-specific diagnosed prevalent population of Immune Complex Membranoproliferative Glomerulonephritis in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.

• The total diagnosed prevalent population of Immune Complex Membranoproliferative Glomerulonephritis in the 7MM was found to be approximately 7,000 in 2023, which is expected to grow during the forecast period 2024-2034.
• The diagnosed prevalent population of Immune Complex Membranoproliferative Glomerulonephritis, in the United States, was found to be approximately 4,000 in 2023.
• In EU4 and the UK, the diagnosed prevalent population of Immune Complex Membranoproliferative Glomerulonephritis was found to be the maximum in Germany, followed by Spain in 2023. While the lowest number of cases were found in Italy.
• In Japan, adults are more prevalent towards Immune Complex Membranoproliferative Glomerulonephritis compared to the pediatric group.

Immune Complex Membranoproliferative Glomerulonephritis Drug Chapters

The drug chapter segment of the Immune Complex Membranoproliferative Glomerulonephritis report encloses a detailed analysis of the marketed and the late-stage (Phase III and Phase II) pipeline drug. Furthermore, the current key players for emerging drugs and their respective drug candidates include Novartis Pharmaceuticals (iptacopan) and Apellis Pharmaceuticals (pegcetacoplan). The drug chapter also helps understand the Immune Complex Membranoproliferative Glomerulonephritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

Emerging Drugs

Iptacopan (LNP023): Novartis Pharmaceuticals

Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of CDRDs8-10. It is the most advanced asset in the Novartis nephrology pipeline and has the potential to become the first targeted therapy to delay progression to dialysis in C3G9. Discovered at the Novartis Institutes for BioMedical Research, iptacopan is currently in development for several CDRDs where significant unmet needs exist, including Immune Complex Membranoproliferative Glomerulonephritis. Currently, the drug is being investigated in Phase III of the clinical development.

Novartis intends to seek regulatory approval for the drug by 2026, with the preliminary findings from the Phase III APPARENT trials expected to be available by the same year.

Pegcetacoplan (APL-2): Apellis Pharmaceuticals

Apellis' Pegcetacoplan (APL-2) is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. It is a15-amino acid cyclic peptide conjugated to each end of a linear polyethylene glycol molecule that binds to C3 and C3b, directly preventing activation of C3, C5, and the alternative pathway. Pegcetacoplan (marketed as EMPAVELI) is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

In October 2020, the company initiated the Phase II (NOBLE) trial in up to 12 patients with post-kidney transplant recurrence of C3G or Immune Complex Membranoproliferative Glomerulonephritis. In September 2021, the first patients dosed in the NOBLE trial. In June 2022, the first patient was dosed in the VALIANT Phase III study investigating pegcetacoplan in C3G or Immune Complex Membranoproliferative Glomerulonephritis. Currently, the drug is evaluated in a Phase III trial for Immune Complex Membranoproliferative Glomerulonephritis patients.

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Renin-angiotensin-aldosterone system inhibitors: Angiotensin receptor blocker (ARB) and angiotensin-converting enzyme (ACE) inhibitors both are used to treat hypertension in C3G. Combination use of RAAS inhibitors showed higher efficiency compared with monotherapy and was associated with a higher incidence of adverse events.

Immunosuppressants: Corticosteroids, calcineurin inhibitors, corticosteroids in combination with mycophenolate mofetil (MMF), and others are used for the treatment of C3G. Among all nonspecific immunosuppressive therapies, MMF-based treatment is promising compared with others concerning clinical remission and renal survival.

Complement inhibitors are the primary class in the emerging pipeline for C3G therapy. Complement inhibitors Pegcetacoplan and Iptacopan perform well in C3G in terms of safety and effectiveness.

Note: Detailed insights will be provided in the final report.

Immune Complex Membranoproliferative Glomerulonephritis Market Outlook

Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is an ultrarare, chronic, and progressive nephropathy, which is characterized by significant immunoglobulin deposition and is assumed to involve dysregulation of both the classical and alternative pathways of complement (AP).

Immune Complex Membranoproliferative Glomerulonephritis lacks approved medications, creating a significant demand for treatments addressing the root cause. Kidney failure, necessitating dialysis or transplantation, can occur within 5-10 years of diagnosis. Current strategies involve supportive measures with or without traditional immunosuppression, showing limited effectiveness in slowing disease progression. Considering the diseases' pathophysiology, a logical approach involves targeted complement inhibition.

The utilization of off-label prescription medications predominantly characterizes the market. Immune Complex Membranoproliferative Glomerulonephritis treatments encompass immunosuppressants, steroids, inhibitors of renin-angiotensin-aldosterone system (RAAS), and other supportive therapies like calcineurin inhibitors, additional immunosuppressive agents, and antibodies.

The current evolving landscape of Immune Complex Membranoproliferative Glomerulonephritis treatment exhibits a mid-level pipeline. Two promising therapies, Iptacopan (Novartis Pharmaceutical) and Pegcetacoplan (Apellis Pharmaceuticals), are in the advanced Phase III developmental stage.

• The market size for IC-MPGN in the US was approximately USD 12 million in 2023, which is expected to increase due to the launch of emerging therapies.
• Among EU4 and the UK, Germany captured the maximum revenue share, followed by Spain and France in 2023.
• Apellis Pharmaceuticals' pegcetacoplan is expected to get a first-mover advantage in IC-MPGN than Novartis' iptacopan.
• There is a pressing demand for innovative IC-MPGN treatments. A promising avenue lies in addressing the initial phases of the complement cascade using inhibitors. Strategically blocking specific complement proteins as a therapeutic measure could potentially modify inflammation triggered by complement and mitigate kidney damage in conditions where the complement system contributes to kidney-related problems.

Immune Complex Membranoproliferative Glomerulonephritis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. Iptacopan is an oral small-molecule inhibitor of complement factor B with potential immunomodulatory activity. Novartis intends to seek regulatory approval for the drug by 2026. The drug is expected to launch in the US in 2027.

Further detailed analysis of emerging therapies drug uptake in the report…

Immune Complex Membranoproliferative Glomerulonephritis Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III and II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Immune Complex Membranoproliferative Glomerulonephritis emerging therapies.

KOL Views:

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, nephrologists, Consultant Nephrologists, and Honorary Associate Professor at University Hospitals of Leicester NHS Trust, and others.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapy treatment patterns or Immune Complex Membranoproliferative Glomerulonephritis market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The development of drugs targeting the complement system is picking up speed, but it comes with several challenges. While the general role of complement in the body is acknowledged, how it contributes to disease and its impact on pathogenesis remains unclear. The complement system is intricate, comprising numerous pathways with regulatory functions. Even if one pathway is blocked, the system can adapt by "redirecting" to another, using regulatory mechanisms to safeguard the body from pathogens. This adaptability poses a challenge in achieving the desired clinical effects of complement inhibitors.

Developing drugs that can successfully block the complement pathway presents a significant challenge. This encompasses choosing appropriate indications, screening potential targets within the complement system, and determining drug types (such as monoclonal antibodies, small molecules, peptides, etc.). When discussing reimbursement for complement inhibitors, there is a possibility that drugs being researched for Immune Complex Membranoproliferative Glomerulonephritis might receive reimbursement in certain countries without encountering obstacles, especially when the same drugs are already reimbursed for other indications.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of Immune Complex Membranoproliferative Glomerulonephritis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Immune Complex Membranoproliferative Glomerulonephritis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Immune Complex Membranoproliferative Glomerulonephritis market.

Immune Complex Membranoproliferative Glomerulonephritis Report Insights

• Patient Population
• Therapeutic Approaches
• Immune Complex Membranoproliferative Glomerulonephritis Pipeline Analysis
• Immune Complex Membranoproliferative Glomerulonephritis Market Size and Trends
• Existing and future Market Opportunity

Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Immune Complex Membranoproliferative Glomerulonephritis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the historical and forecasted Immune Complex Membranoproliferative Glomerulonephritis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• What was the Immune Complex Membranoproliferative Glomerulonephritis total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors for this growth?
• What are the advantages of complement inhibitors over immunosuppressants?
• What will be the impact on market size after the launch of pegcetacoplan and iptacopan in Immune Complex Membranoproliferative Glomerulonephritis?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• Which complement inhibitor generated the highest revenue by 2034?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Immune Complex Membranoproliferative Glomerulonephritis.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of IC-MPGN

4. IC-MPGN Market Overview at a Glance

• 4.1. Market Share by Therapies (%) Distribution of IC-MPGN in 2023 in the 7MM
• 4.2. Market Share by Therapies (%) Distribution of IC-MPGN in 2034 in the 7MM

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Pathogenesis
• 7.4. Clinical Presentation
• 7.5. Histological Patterns
• 7.6. Diagnosis
  • 7.6.1. Kidney Disease Improving Global Outcomes (KDIGO) 2021: Guidelines for Diagnosis
  • 7.6.2. Challenges in Diagnosis

8. Treatment

• 8.1. Idiopathic IC-MPGN

9. Clinical Practice Guideline for the Management of Glomerular Diseases: KDIGO 2021

• 9.1. ICGN
• 9.2. Algorithm for Management of C3G or IC-MPGN

10. Epidemiology and Patient Population

• 10.1. Key Findings
• 10.2. Assumptions and Rationales for IC-MPGN
• 10.3. Total Diagnosed Prevalent Population of IC-MPGN in the 7MM
• 10.4. The United States
  • 10.4.1. Total Diagnosed Prevalent Population of IC-MPGN in the United States
  • 10.4.2. Gender-specific Diagnosed Prevalent Population of IC-MPGN in the United States
  • 10.4.3. Age-specific Diagnosed Prevalent Population of IC-MPGN in the United States
• 10.5. EU4 and the UK
  • 10.5.1. Total Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK
  • 10.5.2. Gender-specific Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK
  • 10.5.3. Age-specific Diagnosed Prevalent Population of IC-MPGN in EU4 and the UK
• 10.6. Japan
  • 10.6.1. Total Diagnosed Prevalent Population of IC-MPGN in Japan
  • 10.6.2. Gender-specific Diagnosed Prevalent Population of IC-MPGN in Japan
  • 10.6.3. Age-specific Diagnosed Prevalent Population of IC-MPGN in Japan

11. Patient Journey

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Iptacopan (LNP023): Novartis Pharmaceuticals
  • 12.2.1. Product Description
  • 12.2.2. Clinical Development
    • 12.2.2.1. Clinical Trials Information
• 12.3. Pegcetacoplan (APL-2): Apellis Pharmaceuticals
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Safety and Efficacy

13. IC-MPGN: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Total Market Size of IC-MPGN in the 7MM
• 13.3. Market Outlook
• 13.4. Conjoint Analysis
• 13.5. Key Market Forecast Assumptions
• 13.6. The United States Market Size
  • 13.6.1. Total Market Size of IC-MPGN in the United States
  • 13.6.2. Market Size of IC-MPGN by Therapies in the United States
• 13.7. EU4 and the UK Market Size
  • 13.7.1. Total Market Size of IC-MPGN in EU4 and the UK
  • 13.7.2. Market Size of IC-MPGN by Therapies in EU4 and the UK
• 13.8. Japan Market Size
  • 13.8.1. Total Market Size of IC-MPGN in Japan
  • 13.8.2. Market Size of IC-MPGN by Therapies in Japan

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW
• 16.4. IC-MPGN: Market Access and Reimbursement
  • 16.4.1. Patient Access Programs
  • 16.4.2. HTA Decisions

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight